MDxHealth's Methylation Based Companion Diagnostics Enables Better Personalized Treatment in Brain Cancer
(Thomson Reuters ONE) -
Data to be Presented at ASCO from RTOG 0525 International Phase III Trial of
Temozolomide
DURHAM, NC, and LIEGE, BELGIUM - May 31, 2011 - MDxHealth SA (NYSE Euronext:
MDXH), a leading molecular diagnostics company in the field of personalized
cancer treatment, today announced that its MGMT test (PredictMDx(TM) for Brain)
has demonstrated success in personalizing brain cancer treatment in a major
international phase III study. The data, obtained from a Phase III study (RTOG
0525) of temozolomide will be presented at the Annual Meeting of the American
Society for Clinical Oncology (ASCO, Chicago, USA, 3-7 June) by principal
investigator Mark R. Gilbert, MD (University of Texas M. D. Anderson Cancer
Center) on Sunday 5(th) June).
MGMT (O6-methylguanine-DNA methyl transferase) is a key DNA repair enzyme
produced by the MGMT gene. When the MGMT gene is methlyated, no MGMT is
produced. The more MGMT present in the tumor, the more active the DNA repair.
This means therapies that work by inducing DNA damage are less likely to be
successful.
About the Study
The RTOG 0525 study was designed as a randomized, international phase III trial
comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule
in newly diagnosed glioblastoma (GBM) patients. The investigators were studying
whether a continuous dose of temozolomide would be more effective than standard
therapy. MDxHealth's MGMT test was used to determine MGMT gene methylation
status and molecular risk classification.
About the MGMT Test: PredictMDx for Brain(TM)
PredictMDx for Brain, MDxHealth's most advanced personalized treatment product
is a test for predicting patient response to alkylating agents, a class of
chemotherapy drugs. The test assesses the methylation status of the MGMT gene,
which is crucial to promoting DNA repair. If the MGMT gene is methylated, cancer
patients tend to respond better to alkylating drug therapy. PredictMDx for Brain
has been shown on thousands of patients to help identify those cancer patients
that are likely to respond to the most commonly used class of brain cancer drugs
(alkylating agents). This patented DNA methylation gene test is attractive for
new brain cancer drug developers since they can more easily target their new
drugs to the patients who usually do not respond to the traditional alkylating
agent drug regime.
About MDxHealth
MDxHealth is a leading molecular diagnostics company that develops and
commercializes oncology-based molecular diagnostic testing for personalized
medicine. The company's tests are based on proprietary gene methylation
technology and assist physicians with the diagnosis of cancer, prognosis of
recurrence risk, and prediction of response to a specific therapy. MDxHealth
collaborates with leading cancer research center such as Johns Hopkins
University and Memorial Sloan Kettering, and major European academic medical
centers. The company has a number of commercial and collaborative partnerships
with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche,
Merck Serono, Pfizer, and other industry leaders. More information can be found
on the Company website:www.mdxhealth.com or on twitter at the following address:
www.twitter.com/mdxhealth.
For more information:
Dr. Jan Groen, CEO Hans Herklots
MDxHealth Capricorn One
+32 4 364 20 70 +41 79 598 7149
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different. MDxHealth expressly
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based unless required by law or regulation
2011-05-31 RTOG ENG:
http://hugin.info/137314/R/1519567/456059.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MdxHealth via Thomson Reuters ONE
[HUG#1519567]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 55130
Anzahl Zeichen: 5587
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 273 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MDxHealth's Methylation Based Companion Diagnostics Enables Better Personalized Treatment in Brain Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
MdxHealth (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
